Sponsor:
argenx
Code:
NCT07760818
Conditions
Sjogrens Disease
Primary Sjögren's Syndrome Painful Sensory Neuropathies
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
efgartigimod PH20 SC
Placebo PH20 SC
Brief summary:
Conditions
Sjogrens Disease
Primary Sjögren's Syndrome Painful Sensory Neuropathies
Study ID
NCT07760818
Start date
Oct 9, 2026
Status verified date
Nov, 2026
Completion date
Jul 28, 2029
Anticipated
Primary completion date
Jul 28, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
75 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Double-blinded treatment period (DBTP): Efgartigimod PH20 SC
placebo comparator: Double-blinded treatment period (DBTP): Placebo PH20 SC
experimental: Open-label treatment period (OLTP)
Interventions
efgartigimod PH20 SC
Placebo PH20 SC
Primary outcome measure
Locations
Sarasota Arthritis Research Center
Recruiting
Sarasota, Florida, United States, 34239
Contacts
Principal Investigator:
Jaishree Manohar, Dr.
Vantage Clinical Trials Tampa
Recruiting
Tampa, Florida, United States, 33614
Contacts
Principal Investigator:
Edgard Janer, Dr.
Revive Research Institute Inc
Recruiting
Sterling Heights, Michigan, United States, 48313
Contacts
Principal Investigator:
Syed Husain, Dr.
Sponsor
argenx
Last update posted
Nov 19, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by argenx on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.